DPP4 and diabetes mellitus: The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) trial (99) was among the first completed studies evaluating DPP-4 inhibitors.